{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:13:19Z","timestamp":1786119199292,"version":"build-2736575974"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,7,15]]},"DOI":"10.1097\/tp.0b013e31817c4ab3","type":"journal-article","created":{"date-parts":[[2009,3,5]],"date-time":"2009-03-05T14:40:54Z","timestamp":1236264054000},"page":"36-45","source":"Crossref","is-referenced-by-count":75,"title":["The Use of Exenatide in Islet Transplant Recipients with Chronic Allograft Dysfunction: Safety, Efficacy, and Metabolic Effects"],"prefix":"10.1097","volume":"86","author":[{"given":"Tatiana","family":"Froud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel N.","family":"Faradji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonello","family":"Pileggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shari","family":"Messinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Baidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaston M.","family":"Ponte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo E.","family":"Cure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Monroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Mendez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennaro","family":"Selvaggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camillo","family":"Ricordi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo","family":"Alejandro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-9-20210129","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.2337\/diabetes.52.7.1595","article-title":"Islet transplantation: A brave new world.","volume":"52","author":"Ricordi","year":"2003","journal-title":"Diabetes"},{"key":"R2-9-20210129","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJM200007273430401","article-title":"Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen.","volume":"343","author":"Shapiro","year":"2000","journal-title":"N Engl J Med"},{"key":"R3-9-20210129","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa061267","article-title":"International trial of the Edmonton protocol for islet transplantation.","volume":"355","author":"Shapiro","year":"2006","journal-title":"N Engl J Med"},{"key":"R4-9-20210129","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.2337\/diabetes.54.7.2060","article-title":"Five-year follow-up after clinical islet transplantation.","volume":"54","author":"Ryan","year":"2005","journal-title":"Diabetes"},{"key":"R5-9-20210129","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1111\/j.1600-6143.2005.00957.x","article-title":"Islet transplantation in type 1 diabetes mellitus using cultured islets and steroid-free immunosuppression: Miami experience.","volume":"5","author":"Froud","year":"2005","journal-title":"Am J Transplant"},{"key":"R6-9-20210129","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1600-6143.2005.01174.x","article-title":"Quality of life after islet transplantation.","volume":"6","author":"Poggioli","year":"2006","journal-title":"Am J Transplant"},{"key":"R7-9-20210129","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/01.mot.0000203878.00901.26","article-title":"Islet transplantation: Steady progress and current challenges.","volume":"11","author":"Pileggi","year":"2006","journal-title":"Curr Opin Organ Transplant"},{"key":"R8-9-20210129","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1172\/JCI112720","article-title":"Natural history of intrahepatic canine islet cell autografts.","volume":"78","author":"Alejandro","year":"1986","journal-title":"J Clin Invest"},{"key":"R9-9-20210129","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1097\/01.TP.0000081043.23751.81","article-title":"Elevated portal vein drug levels of sirolimus and tacrolimus in islet transplant recipients: Local immunosuppression or islet toxicity?","volume":"76","author":"Desai","year":"2003","journal-title":"Transplantation"},{"key":"R10-9-20210129","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/00007691-200502000-00008","article-title":"The portal immunosuppressive storm: Relevance to islet transplantation?","volume":"27","author":"Shapiro","year":"2005","journal-title":"Ther Drug Monit"},{"key":"R11-9-20210129","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.2337\/diabetes.53.9.2281","article-title":"Assessment of cytotoxic lymphocyte gene expression in the peripheral blood of human islet allograft recipients: Elevation precedes clinical evidence of rejection.","volume":"53","author":"Han","year":"2004","journal-title":"Diabetes"},{"key":"R12-9-20210129","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1097\/00007890-199604270-00027","article-title":"Evidence of recurrent autoimmunity in human allogeneic islet transplantation.","volume":"61","author":"Stegall","year":"1996","journal-title":"Transplantation"},{"key":"R13-9-20210129","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMc061530","article-title":"Autoimmunity after islet-cell allotransplantation.","volume":"355","year":"2006","journal-title":"N Engl J Med"},{"key":"R14-9-20210129","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1097\/00007890-199911270-00017","article-title":"The effects of maintenance doses of FK506 versus cyclosporin A on glucose and lipid metabolism after orthotopic liver transplantation.","volume":"68","author":"Fernandez","year":"1999","journal-title":"Transplantation"},{"key":"R15-9-20210129","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.2337\/db06-0173","article-title":"Sirolimus is associated with reduced islet engraftment and impaired beta-cell function.","volume":"55","author":"Zhang","year":"2006","journal-title":"Diabetes"},{"key":"R16-9-20210129","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1172\/JCI112855","article-title":"Insulinotropin: glucagon-like peptide I (7\u201337) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas.","volume":"79","author":"Mojsov","year":"1987","journal-title":"J Clin Invest"},{"key":"R17-9-20210129","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0014-5793(87)81430-8","article-title":"Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut.","volume":"211","author":"Holst","year":"1987","journal-title":"FEBS Lett"},{"key":"R18-9-20210129","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1073\/pnas.84.10.3434","article-title":"Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line.","volume":"84","author":"Drucker","year":"1987","journal-title":"Proc Natl Acad Sci USA"},{"key":"R19-9-20210129","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.2337\/diabetes.48.12.2270","article-title":"Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats.","volume":"48","author":"Xu","year":"1999","journal-title":"Diabetes"},{"key":"R20-9-20210129","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2337\/diabetes.49.5.741","article-title":"Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas.","volume":"49","author":"Stoffers","year":"2000","journal-title":"Diabetes"},{"key":"R21-9-20210129","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.1210\/en.2002-220405","article-title":"Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats.","volume":"143","author":"Farilla","year":"2002","journal-title":"Endocrinology"},{"key":"R22-9-20210129","doi-asserted-by":"crossref","first-page":"5145","DOI":"10.1210\/en.2003-1147","article-title":"Glucagon-like peptide-1 and the islet beta-cell: Augmentation of cell proliferation and inhibition of apoptosis.","volume":"144","author":"Drucker","year":"2003","journal-title":"Endocrinology"},{"key":"R23-9-20210129","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.2337\/diacare.28.5.1092","article-title":"Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.","volume":"28","author":"DeFronzo","year":"2005","journal-title":"Diabetes Care"},{"key":"R24-9-20210129","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2337\/diacare.28.5.1083","article-title":"Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.","volume":"28","author":"Kendall","year":"2005","journal-title":"Diabetes Care"},{"key":"R25-9-20210129","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.2337\/diacare.27.11.2628","article-title":"Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.","volume":"27","author":"Buse","year":"2004","journal-title":"Diabetes Care"},{"key":"R26-9-20210129","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.1463-1326.2006.00589.x","article-title":"Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus.","volume":"8","author":"Ratner","year":"2006","journal-title":"Diabetes Obes Metab"},{"issue":"suppl 3","key":"R28-9-20210129","first-page":"340","article-title":"Islet alone and islet after kidney transplantation at the University of Miami: An update.","volume":"82","author":"Faradji","year":"2006","journal-title":"Transplantation"},{"key":"R29-9-20210129","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1600-6143.2006.01620.x","article-title":"Simple measures to monitor \u03b2-cell mass and assess islet graft dysfunction.","volume":"7","author":"Faradji","year":"2007","journal-title":"Am J Transplant"},{"issue":"2 suppl. 1","key":"R30-9-20210129","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/00007890-200407271-00463","article-title":"Acute insulin release to intravenous glucose is the best indicator of islet allograft dysfunction.","volume":"78","author":"Baidal","year":"2004","journal-title":"Transplantation"},{"key":"R31-9-20210129","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1097\/01.tp.0000203858.41105.88","article-title":"Reversal of diabetes by pancreatic islet transplantation into a subcutaneous, neovascularized device.","volume":"81","author":"Pileggi","year":"2006","journal-title":"Transplantation"},{"key":"R32-9-20210129","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nri1332","article-title":"Clinical islet transplantation: Advances and immunological challenges.","volume":"4","author":"Ricordi","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"R33-9-20210129","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.diabres.2006.03.022","article-title":"Effect of glucagon-like peptide-1 (7\u201337) on beta-cell function after islet transplantation in type 1 diabetes.","volume":"74","author":"Fung","year":"2006","journal-title":"Diabetes Res Clin Pract"},{"key":"R34-9-20210129","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/S0006-2952(01)00924-8","article-title":"Exendin-4 increases insulin sensitivity via a PI-3-kinase-dependent mechanism: contrasting effects of GLP-1.","volume":"63","author":"Idris","year":"2002","journal-title":"Biochem Pharmacol"},{"key":"R35-9-20210129","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1053\/meta.2001.22519","article-title":"Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro.","volume":"50","author":"Parkes","year":"2001","journal-title":"Metabolism"},{"key":"R36-9-20210129","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s00125-006-0251-2","article-title":"Exendin-4 treatment improves metabolic control after rat islet transplantation to athymic mice with streptozotocin-induced diabetes.","volume":"49","author":"Sharma","year":"2006","journal-title":"Diabetologia"},{"key":"R37-9-20210129","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1074\/jbc.M209423200","article-title":"Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis.","volume":"278","author":"Li","year":"2003","journal-title":"J Biol Chem"},{"key":"R38-9-20210129","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.2337\/diabetes.50.7.1562","article-title":"Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age.","volume":"50","author":"Tourrel","year":"2001","journal-title":"Diabetes"},{"key":"R39-9-20210129","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.2337\/diabetes.51.5.1443","article-title":"Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4.","volume":"51","author":"Tourrel","year":"2002","journal-title":"Diabetes"},{"key":"R40-9-20210129","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1007\/s00125-002-0828-3","article-title":"Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db\/db mice.","volume":"45","author":"Wang","year":"2002","journal-title":"Diabetologia"},{"key":"R41-9-20210129","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2337\/diabetes.52.2.365","article-title":"Role of endogenous glucagon-like peptide-1 in islet regeneration after partial pancreatectomy.","volume":"52","author":"De Leon","year":"2003","journal-title":"Diabetes"},{"key":"R42-9-20210129","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/01.tp.0000251379.46596.2d","article-title":"Effect of exenatide on beta cell function after islet transplantation in type 1 diabetes mellitus.","volume":"15","author":"Ghofaili","year":"2007","journal-title":"Transplantation"},{"issue":"S2","key":"R43-9-20210129","first-page":"574","article-title":"The effect of exenatide in islet graft function and insulin independence after supplemental islet infusions.","volume":"7","author":"Faradji","year":"2007","journal-title":"AJT"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00007890-200807150-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:43:35Z","timestamp":1786038215000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00007890-200807150-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7,15]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0b013e31817c4ab3","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2008,7,15]]}}}